Rosa Rodriguez-Monguio

University of Massachusetts

Assistant Professor

Department of Operations and Information Managemen

Amherst, MA 01003

United States

SCHOLARLY PAPERS

4

DOWNLOADS

277

SSRN CITATIONS

1

CROSSREF CITATIONS

3

Scholarly Papers (4)

1.

Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980-2009

Journal of Law, Medicine and Ethics, p. 688, Fall 2013, Boston Univ. School of Law, Law and Economics Research Paper No. 13-47
Number of pages: 10 Posted: 18 Sep 2013 Last Revised: 08 Aug 2015
Boston University School of Law, George Washington University, Director International Center for Pharmaceutical Economics and Policy, University of Massachusetts and Brigham and Women's Hospital/Harvard Medical School
Downloads 217 (177,115)
Citation 1

Abstract:

Loading...

antibiotics, innovation, resistance

2.

Health Information Technologies: Which Nursing Homes Adopted Them?

Number of pages: 24 Posted: 26 Feb 2016
Ning Zhang, Susan F. Lu, Biao Xu, Bingxiao Wu, Rosa Rodriguez-Monguio and Jerry Gurwitz
University of Massachusetts Amherst, Purdue University - Krannert School of Management, Nanjing University, Rutgers University, University of Massachusetts and University of Massachusetts Worcester - University of Massachusetts Medical School
Downloads 60 (441,252)
Citation 1

Abstract:

Loading...

health information technology; nursing home; long term care; quality of care

3.

Public Procurement and Price Discrimination of Antiretroviral Therapy

iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 22 Jun 2007
Rosa Rodriguez-Monguio and Enrique Seoane
University of Massachusetts and Director International Center for Pharmaceutical Economics and Policy

Abstract:

Loading...

Price Negotiations, Price Discrimination, Antiretrovirals

4.

Effective Patent Life of Antiretroviral Drugs in the U.S 1987-2006

iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 21 Jun 2007
Enrique Seoane and Rosa Rodriguez-Monguio
Director International Center for Pharmaceutical Economics and Policy and University of Massachusetts

Abstract:

Loading...

antiretroviral drugs, new molecular entities, patents, exclusivity, U.S.FDA.